ALHAMBRA, Calif., March 6, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that leadership is presenting at the following investor conferences.
Jefferies Value-Based Healthcare Summit
Date: Monday, March 13, 2023, at 11 a.m. PT/2 p.m. ET
Venue: W South Beach, Miami Beach
Barclays Global Healthcare Conference
Date: Tuesday, March 14, 2023, at 11:35 a.m. PT/2:35 p.m. ET
Venue: Loews Miami Beach Hotel, Miami Beach
Oppenheimer 33rd Annual Healthcare Conference (Virtual)
Date: Tuesday, March 14, 2023, at 12:20 p.m. PT/3:20 p.m. ET
Management will also be participating in one-on-one meetings at these events. Those interested in attending any of these conferences should reach out to their respective representatives. The Company's presentation at the Barclays Global Healthcare Conference will be made available via live webcast and in archive following the conclusion of the event at the "Events" page of the Company's website: https://www.apollomed.net/news-media/events.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
This email address is being protected from spambots. You need JavaScript enabled to view it.
Carolyne Sohn, The Equity Group
(408) 538-4577
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$32.70 |
Daily Change: | -1.06 -3.14 |
Daily Volume: | 238,482 |
Market Cap: | US$1.490B |
November 08, 2024 November 07, 2024 July 15, 2024 May 07, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load